Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FNS007 vs placebo and tofacitinib in moderate to severe rheumatoid arthritis (Phase 2, China)
ChiCTR2600120353Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FNS007 in rheumatoid arthritis (RA) (4 arms), sponsored by Peking University People's Hospital. Primary endpoints: ACR20 response rate at Week 12 and Incidence of adverse events at Week 12. Started Mar 2026; status: recruiting.
02
Drugs
FNS007
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2600120353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120353.